PHARMAENGINE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.6 TWD | +1.08% |
|
-5.26% | -11.28% |
| Sales 2024 * | 851M 26.25M | Sales 2025 * | - | Capitalization | 13.45B 415M |
|---|---|---|---|---|---|
| Net income 2024 * | 269M 8.3M | Net income 2025 * | - | EV / Sales 2024 * | 15.8 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
50.6
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
2.46% | Yield 2025 * |
-
| Free-Float | 62.94% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +1.08% | ||
| 1 week | -5.26% | ||
| Current month | -5.65% | ||
| 1 month | +0.43% | ||
| 3 months | -4.78% | ||
| 6 months | +3.65% | ||
| Current year | -11.28% |
1 week
90.70
98.50
1 month
90.70101.50
Current year
90.70115.00
1 year
79.80122.50
3 years
53.20150.50
5 years
33.10150.50
10 years
33.10246.55
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Ren Wang
CEO | Chief Executive Officer | - | - |
Yu Syuan Tsao
DFI | Director of Finance/CFO | - | 21-05-16 |
Po Nien Shen
CTO | Chief Tech/Sci/R&D Officer | - | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jui Wen Wu
BRD | Director/Board Member | - | 18-01-18 |
Zhi Li Wang
BRD | Director/Board Member | - | 19-06-12 |
Yi Hui Lin
BRD | Director/Board Member | - | 18-05-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -1.38% | - | |
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 93.6 | +1.08% | 239,294 |
| 24-04-17 | 92.6 | +1.76% | 560,609 |
| 24-04-16 | 91 | -3.29% | 1,179,505 |
| 24-04-15 | 94.1 | -3.09% | 1,091,172 |
| 24-04-12 | 97.1 | -0.82% | 566,160 |
End-of-day quote Taipei Exchange, April 17, 2024
More quotes
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
93.6
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.28% | 410M | |
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
- Stock Market
- Equities
- 4162 Stock
